Americas Dominates the Global Influenza Vaccine Market | Technavio

Technavio has published a new market research report on the global influenza vaccine market 2018-2022 under their healthcare and life sciences library. (Graphic: Business Wire)

LONDON--()--The latest market research report by Technavio on the global influenza vaccine market predicts a CAGR of above 7% during the period 2018-2022.

The report segments the global influenza vaccine market by vaccine type (live attenuated influenza vaccines and recombinant influenza vaccines) and by geography (the Americas, EMEA, and APAC). It provides a detailed illustration of the major factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Here are some key findings of the global influenza vaccine market, according to Technavio healthcare and life sciences researchers:

  • Strong pipeline: a major market trend
  • In 2017, the live attenuated influenza vaccines segment dominated the market by occupying almost 76% share
  • The Americas dominated the global influenza vaccine market with 43% share in 2017
  • AstraZeneca, CSL, GlaxoSmithKline, and Sanofi are the leading players in the market

Save more with Technavio. Buy 2 reports and get the third for free: View Technavio’s latest discounts and promotions

Live attenuated influenza vaccines segment dominates the market

To prevent serious diseases in people with a healthy immune system, live attenuated influenza vaccines are prepared by weakening the natural microbes which are usually viruses. For the prevention of influenza, several approved live attenuated influenza vaccines are available in the market. As several new product launches are expected during the forecast period, the global live attenuated influenza vaccines market is expected to witness a high growth considering the impressive number of molecules in Phase III clinical trials.

The extensive R&D is expected to benefit the market by improving versions of existing products. For example, VAXAGRIP, launched by Sanofi, provide protection against four strains of influenza virus and is upgraded than the earlier trivalent version of the product. Such products lead to improved outcomes by offering enhanced protection against more strains of the virus.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Americas: largest influenza vaccine market

Technavio researchers anticipate high growth for the global influenza vaccine market in the Americas due to the availability of 151 million to 166 million doses of injectable flu vaccine, as projected by vaccine manufacturers during 2017-18. The US witnessed a strong influenza season due to the well-established healthcare infrastructure, which contributed to the highest market share in the Americas. The well-defined surveillance system in the country to track the prevalence rate of influenza has further strengthened its strategies to use prophylaxis measure against it.

According to a senior analyst at Technavio for research on vaccines, “During the forecast period, the influenza market in the Americas is expected to grow at a moderate pace. Improving awareness is one of the factors contributing to the market growth, which is indicated by the rise in self-reported flu vaccination. Adoption and demand for influenza vaccine is expected to increase in this region due to the rise in awareness rate.”

Competitive vendor landscape

The global influenza vaccines market is moderately concentrated. With many players in the market, the competition for expansion increases. As a result, the key players are increasing their number of partnerships and acquisitions to integrate various technologies and increase their foothold in the market. Quality, regulatory compliance, and innovation are the major factors of differentiation in the market.

Get a sample copy of the global influenza vaccine market report free of cost

Access Technavio’s continuously growing vaccines research library and find expert analysis on hundreds of markets.

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

The latest market research report by Technavio on the global influenza vaccine market predicts a CAGR of above 7% during the period 2018-2022.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200